Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Bruker Daltonics and Isis in Biosensor Alliance

By HospiMedica staff writers
Posted on 09 Aug 2006
A new alliance between Bruker Daltonics (Billerica, MA, USA), a subsidiary of Bruker BioSciences, and Isis Pharmaceuticals (Carlsbad, CA, USA) has been announced for the manufacturing and distribution of a new Ibis T5000 biosensor system. More...
This universal biosensor system can simultaneously identify thousands of types of infectious organisms in a sample.

Under the terms of the agreement, Bruker Daltonics will be the exclusive worldwide manufacturer of the Ibis T5000 biosensor system, which incorporates Bruker Daltonics' microtof electrospray ionization (esi)-tof (time of flight), or ESI-TOF, mass spectrometer. Bruker Daltonics will also be responsible for order processing, system installations, and service in North America, Europe and the Middle East. In Europe and the Middle East, Bruker Daltonics will have exclusive rights to sell Ibis T5000 systems and Ibis infectious organism identification kits for various government applications, and will have non-exclusive rights to sell to all other customers. Outside of Bruker Daltonics' exclusive market, Isis may sell Ibis T5000s and its infectious organism identification kits.

The Ibis T5000 utilizes the triangulation identification for the genetic evaluation of risks (TIGER) methodology, which is a combination of genomics, mathematical modeling, mass spectrometry, and molecular amplification to generate a "fingerprint” of each bacterium or virus, allowing it to identify virtually any bacteria or virus present in a sample. The Ibis T5000 biosensor system can rapidly identify or classify organisms that are newly-emerging, genetically altered, or unable to be cultured. The Ibis T5000 biosensor works with many different types of infectious samples from human samples, such as throat swabs or sputum, and environmental samples, such as soil or air.

Ibis plans to commercialize the Ibis T5000 biosensor system and associated reagents to government customers for use in biowarfare defense, epidemiologic surveillance, and forensics; and to non-government customers for use in pharmaceutical process control, hospital-associated infection control, and infectious disease diagnostics. The Ibis T5000 is currently designated for research use only (RUO) and has not yet been approved for any regulated uses, including in vitro diagnostics.

Bruker Daltonics develops innovative life science tools based on mass spectrometry, and also offers a broad line of nuclear, biologic and chemical detection products for homeland security.



Related Links:
Bruker Daltonics
Isis Pharmaceuticals

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.